Ken Griffin Neogenomics Inc Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Neogenomics Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 152,000 shares of NEO stock, worth $2.47 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
152,000
Previous 111,700
36.08%
Holding current value
$2.47 Million
Previous $1.76 Million
20.11%
% of portfolio
0.0%
Previous 0.0%
Shares
24 transactions
Others Institutions Holding NEO
# of Institutions
278Shares Held
127MCall Options Held
581KPut Options Held
107K-
Black Rock Inc. New York, NY19.7MShares$320 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.1MShares$230 Million0.0% of portfolio
-
Brown Advisory Inc8.77MShares$143 Million0.16% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.73MShares$110 Million0.06% of portfolio
-
Janus Henderson Group PLC London, X06.62MShares$108 Million0.05% of portfolio
About NEOGENOMICS INC
- Ticker NEO
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 125,796,000
- Market Cap $2.05B
- Description
- NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytoge...